Hjort, Line
Bredgaard, Sandra Stokholm
Manitta, Eleonora
Marques, Irene
Sørensen, Anja Elaine
Martino, David
Grunnet, Louise Groth
Kelstrup, Louise
Houshmand-Oeregaard, Azadeh
Clausen, Tine Dalsgaard
Mathiesen, Elisabeth Reinhardt
Olsen, Sjurdur Frodi
Saffery, Richard
Barrès, Romain
Damm, Peter
Vaag, Allan Arthur
Dalgaard, Louise Torp
Funding for this research was provided by:
Fhv. Dir. Leo Nielsen og Hustru Karen Margrethe Nielsens Legat for Lægevidenskabelig Grundforskning
Civilingeniør Frode V. Nyegaard og Hustru’s Fond
A.P. Møller Fonden
Lægeforeningens Forskningfond
Novo Nordisk Fonden (NNF17SA0031406, NNF17SA0031406, NNF17SA0031406, NNF17SA0031406, NNF17SA0031406)
The Danish Diabetes Association
Novo Nordisk Foundation Center for Basic Metabolic Research (NNF18CC0034900, NNF18CC0034900)
The Innovation Fund Denmark (09-067124, 09-067124, 09-067124, 09-067124, 09-067124, 09-067124, 09-067124)
Article History
Received: 12 January 2024
Accepted: 20 April 2024
First Online: 7 May 2024
Declarations
:
: The Danish National Birth Cohort (DNBC): The study was approved by the Regional Scientific Ethics Committee for the municipalities of Copenhagen and Frederiksberg (H-4–2011–045 and H-4–2013–129). Consent from both parents was essential for the participation of the child in the study. All procedures were in accordance with the Declaration of Helsinki II. The clinical follow-up study followed the same procedures with regard to consent and approval of study protocols (H-4–2011-045 and H-4-2013-129). The Copenhagen Cohort (CoCo): The protocol was approved by the local ethical committee in Copenhagen and Frederiksberg municipality (KF 11-152/04 and KF 01-061/03) and in accordance with the Helsinki declaration. Written as well as oral informed consent was obtained from all participants. The studies are not registered in ClinicalTrials.gov. Both are observational cohorts with no intervention, and at the time of establishment of the cohorts, it was not custom to register such trials.
: The manuscript is approved by all authors for publication.
: L.G.G., L.K. and L.T.D. own shares in Novo Nordisk A/S. A.H.-O. is an employee of Novo Nordisk A/S and owns shares in the company. After initiation of this work, A.H.-O. became employed by Novo Nordisk A/S, but Novo Nordisk A/S was not involved in this project. The remaining authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.